The trial results take the company a step closer to acquiring a share of the multi-billion dollar market for depression drugs.
Axsome depression drug meets late-stage study goal, shares soar 56%
More from Industry NewsMore posts in Industry News »
- Bausch, Clearside receive U.S. approval for eye injection
- Priority list being drawn up of kids with comorbidities for vaccine rollout
- Namibia halts use of Sputnik jabs after South Africa HIV fears
- We are waiting for DCGI approval for children’s Covid-19 vaccine: Bharat Biotech Chairman
- Covid-19: ICMR and task force stress on completing adult vaccination